Literature DB >> 33264050

The challenges of radioiodine treatment for incontinent paediatric patients with complex care needs.

Nathan Dickinson1, Jennifer Poveda1, Claire Greaves1, Charnie Kalirai1, Rachel Smith1.   

Abstract

OBJECTIVE: A thyrotoxic paediatric patient with incontinence, autism and Down's syndrome was referred for radioiodine therapy. Here, the risk assessment methodology and measures taken to deliver a legally compliant treatment that was acceptable to the family are described.
METHODS: Prior risk assessment indicated that the most active incontinence waste would require decay storage until it could be transported for disposal. The Health and Safety Executive (HSE) indicated that school staff would be occupationally exposed under the Ionising Radiations Regulations (2017) based on the patient's retained activity. To avoid the need for HSE registration, it was advised that the patient's return to school may need to be delayed slightly. Post-treatment, confirmatory waste and patient dose rate measurements were made to refine the advised time scales.
RESULTS: Domestic waste disposal resumed at 28 days. The patient recommenced schooling a few days after their school reopened after the summer break. The school underwent HSE notification.
CONCLUSION: Careful planning allowed us to provide a safe, compliant treatment regarding waste management and occupational exposure. ADVANCES IN KNOWLEDGE: Incontinent 131I outpatient treatments require detailed, patient specific waste management. The HSE considered school staff as occupationally exposed by the patient well after normal social restrictions had ended.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33264050      PMCID: PMC8011262          DOI: 10.1259/bjr.20200813

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  5 in total

1.  Radionuclide and radiation protection data handbook 2nd edition (2002).

Authors:  D Delacroix; J P Guerre; P Leblanc; C Hickman
Journal:  Radiat Prot Dosimetry       Date:  2002       Impact factor: 0.972

2.  Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism.

Authors:  S F Barrington; M J O'Doherty; A G Kettle; W H Thomson; P J Mountford; D N Burrell; R J Farrell; S Batchelor; P Seed; L K Harding
Journal:  Eur J Nucl Med       Date:  1999-07

3.  Radiation dose to patients from radiopharmaceuticals. A report of a Task Group of Committee 2 of the International Commission on Radiological Protection.

Authors: 
Journal:  Ann ICRP       Date:  1987

4.  Radiation dose rates from adult patients receiving 131I therapy for thyrotoxicosis.

Authors:  M J O'Doherty; A G Kettle; C N Eustance; P J Mountford; A J Coakley
Journal:  Nucl Med Commun       Date:  1993-03       Impact factor: 1.690

5.  Radiological protection guidance for radioactive patients--new data for therapeutic 131I.

Authors:  T E Hilditch; J M Connell; D L Davies; W S Watson; W D Alexander
Journal:  Nucl Med Commun       Date:  1991-06       Impact factor: 1.690

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.